Ionis Pharmaceuticals 2024 Performance ReportFinancial statementsIonis Pharmaceuticals reported a 2024 revenue decline of 11%, with a $475 million operating loss. The report highlights product sales from Spinraza, Wainua, Qalsody, and others, alongside its cash reserves and 2025 guidance.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
